January 06, 2023
During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.
December 30, 2022
During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.
December 20, 2022
The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.
December 19, 2022
During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.
December 14, 2022
During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.
December 12, 2022
December 05, 2022
Adaptive Biotechnologies announced the launch of its clonoSEQ ctDNA-based MRD assay for patients with diffuse large B-cell lymphoma.
November 13, 2022
During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.
November 08, 2022
During a Targeted Oncology case-based roundtable event, Jason Westin, MD, discussed recent clinical trial data for patients with relapsed/refractory diffuse B-cell lymphoma.
October 16, 2022
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants the use of novel therapies for patients with diffuse large B-cell lymphoma.